Evidence map›Paper›PMID 29390362›Full record

ArticleMedicine2017

Malignant transformation of glucagonoma with SPECT/CT In-111 OctreoScan features: A case report.

Giuseppe Corrias, Natally Horvat, Serena Monti, Olca Basturk, Oscar Lin, Luca Saba, Lisa Bodei, Diane L Reidy, Lorenzo Mannelli

Open access · goldAbstract readCase Reports
In one paragraph

Article in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Giuseppe CorriasDepartment of Radiology, Memorial Sloan Kettering Cancer Center, NY Department of Radiology, University of Cagliari, Cagliari, Italy Department of Radiology, Hospital Sírio-Libanês, São Paulo Department of Radiology, Universidade de São Paulo, São Paulo, SP, Brazil IRCCS SDN, Naples, Italy Department of Pathology Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Natally Horvat
Serena Monti
Olca Basturk
Oscar Lin
Luca Saba
Lisa Bodei
Diane L Reidy
Lorenzo Mannelli
Memorial Sloan Kettering Cancer Center · USIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Cagliari · IT

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

rationaleGlucagonoma is an uncommon disease but it has been associated with a pattern of symptoms defined as glucagonoma syndrome. These symptoms, if promptly recognized, could help to speed up the diagnosing process. PATIENT CONCERNS: We report a case of a 68-year-old woman with a pancreatic glucagonoma. Her symptoms at the onset were typical of the glucagonoma syndrome. DIAGNOSES: After a significant weight loss, she underwent a computer tomography scan of the abdomen, which showed a hypervascular lesion of the tail of the pancreas and hypervascular lesions of the liver. An ultrasound guided biopsy was performed and pathology was consistent with glucagonoma. Her blood glucagon levels were elevated. OUTCOMES: She was treated with chemotherapy and somatostatin analogs. After 4 years, the disease had a malignant transformation, and metastases suddenly started to grow up. She stopped being responsive to treatment and eventually passed away. LESSONS: Due to its rarity, clinical diagnosis is challenging and generally it comes after a long interval since the onset of symptoms. Awareness of physicians and dermatologists of the characteristic necrolytic migratory erythema, and of the other symptoms, often leads to early diagnosis.

Indexed as

Single Photon Emission Computed Tomography Computed TomographyAgedCell Transformation, NeoplasticFatal OutcomeFemaleGlucagonomaHumansLiver NeoplasmsOctreotidePancreatic NeoplasmsRadiopharmaceuticalsindium-111-octreotideOctreotideRadiopharmaceuticals

Identifiers

PMID29390362
PMCPMC5815774
OpenAlexW2773294104

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.